Actavis is delighted to announce the launch of Candesartan. Only four weeks after the launch of Quetiapine, it brings Actavis’ total of day-one patent expiries in 2012 to eight, and new launches to the product portfolio an impressive 22.

Candesartan is indicated for the treatment of patients with heart failure and impaired left ventricular systolic function as an add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.

Actavis is offering Candesartan in packs of 28 tablets in 4mg, 8mg, 16mg and 32mg strengths and 7 tablets in 4mg strength.

All products are available through major wholesalers or directly from the Actavis Telemarketing team on telephone: 0800 731 0370 or fax: 0800 731 0380.